Published 2 days ago • loading... • Updated 1 day ago

Exact Sciences Surges to New Heights: 2024 Ends with Groundbreaking Advances

Summary by elblog.pl

Exact Sciences surpassed expectations in 2024 with innovation and resilience, delivering 4.6 million cancer diagnostic test results. The company achieved an 11% increase in core revenue and remarkably expanded operating margins by 48%. Free cash flow doubled, underscoring Exact Sciences’ strong financial performance. FDA approved Cologuard Plus, a next-gen colon cancer screening test, enhancing their diagnostic arsenal alongside Oncodetect and C…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

wisconsintechnologycouncil.com

In Business: Exact Sciences reports revenue growth, confirms 2025 launch of new products - Wisconsin Technology Council

With Chairman and CEO Kevin Conroy predicting that 2025 is on track to be the most productive year in Exact Sciences’ history, the company reported better-than-expected 10% revenue growth for both the fourth quarter of 2024 and 10% revenue growth over the full year during its quarterly earnings call on Wednesday. Best known for its

1 day ago

Read Full Article